Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 19;5(10):e0990. doi: 10.1097/CCE.0000000000000990

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 1. — Top, Absolute lymphocyte counts over time: This timeframe of the absolute lymphocyte counts before, during, and after IL-7 administration shows a transient increase followed by an expected decrease in response to acute acalculous cholecystitis with bacteremia, after which the lymphocyte count continued to trend upward until returning to a near normal level approximately 60 d following injection. The peak value between days 48 and 56 likely reflects the impact of IL-7 given the absence of other associated factors, including administration of G-CSF, GM-CSF, and granulocyte infusions during that period. Bottom, Absolute granulocyte counts over time: This timeframe of the absolute granulocyte counts before, during, and after IL-7 therapy. Note the large increase in the absolute granulocyte count with the onset of cholecystitis and bacteremia. G-CSF = granulocyte-colony stimulating factor, GM-CSF = granulocyte macrophage colony-stimulating factor, IL = interleukin.